Combination chemotherapy in advanced prostate cancer: a silk purse?
BJ Roth
JCO Oct 1 1994: 2001–2002. [PDF]
Brain tumor chemotherapy trials: slow start, but quickly gaining
HA Fine
JCO Oct 1 1994: 2003–2004. [PDF]
	Phase II evaluation of oral estramustine and oral etoposide in hormone- refractory adenocarcinoma of the prostate
	KJ Pienta, B Redman, M Hussain, G Cummings, PS Esper, C Appel, and LE Flaherty
	JCO Oct 1 1994: 2005–2012. [Abstract] [PDF]
	Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group
	G Cairncross, D Macdonald, S Ludwin, D Lee, T Cascino, J Buckner, D Fulton, E Dropcho, D Stewart, and C Schold, Jr
	JCO Oct 1 1994: 2013–2021. [Abstract] [PDF]
	Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
	DC Ihde, JL Mulshine, BS Kramer, SM Steinberg, RI Linnoila, AF Gazdar, M Edison, RM Phelps, M Lesar, and JC Phares
	JCO Oct 1 1994: 2022–2034. [Abstract] [PDF]
	Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil
	GJ Peters, CL van der Wilt, CJ van Groeningen, K Smid, S Meijer, and HM Pinedo
	JCO Oct 1 1994: 2035–2042. [Abstract] [PDF]
	p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients
	ZS Zeng, AS Sarkis, ZF Zhang, DS Klimstra, E Charytonowicz, JG Guillem, C Cordon-Cardo, and AM Cohen
	JCO Oct 1 1994: 2043–2050. [Abstract] [PDF]
	Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome
	FM Foss, DC Ihde, IR Linnoila, AB Fischmann, GP Schechter, JD Cotelingam, SM Steinberg, BC Ghosh, JL Stocker, and A Bastian
	JCO Oct 1 1994: 2051–2059. [Abstract] [PDF]
	Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study
	FL Meyskens, Jr, PY Liu, RJ Tuthill, VK Sondak, WS Fletcher, WR Jewell, W Samlowski, SP Balcerzak, DJ Rector, and RD Noyes
	JCO Oct 1 1994: 2060–2065. [Abstract] [PDF]
	Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer
	AE Taylor, E Wiltshaw, ME Gore, I Fryatt, and C Fisher
	JCO Oct 1 1994: 2066–2070. [Abstract] [PDF]
	First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research
	M Borner, M Bacchi, A Goldhirsch, R Greiner, F Harder, M Castiglione, WF Jungi, B Thurlimann, F Cavalli, and JP Obrecht
	JCO Oct 1 1994: 2071–2077. [Abstract] [PDF]
	Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study
	SE Rivkin, S Green, B Metch, AB Cruz, MD Abeloff, WR Jewell, JJ Costanzi, WB Farrar, JP Minton, and CK Osborne
	JCO Oct 1 1994: 2078–2085. [Abstract] [PDF]
	Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group
	M Schumacher, G Bastert, H Bojar, K Hubner, M Olschewski, W Sauerbrei, C Schmoor, C Beyerle, RL Neumann, and HF Rauschecker
	JCO Oct 1 1994: 2086–2093. [Abstract] [PDF]
	Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study
	G Gasparini, O Caffo, S Barni, L Frontini, A Testolin, RB Guglielmi, and G Ambrosini
	JCO Oct 1 1994: 2094–2101. [Abstract] [PDF]
	Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer
	C Toussaint, J Izzo, M Spielmann, S Merle, F May-Levin, JP Armand, D Lacombe, T Tursz, M Sunderland, and GG Chabot
	JCO Oct 1 1994: 2102–2112. [Abstract] [PDF]
	Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer
	KT Robbins, AM Storniolo, C Kerber, D Vicario, S Seagren, M Shea, C Hanchett, G Los, and SB Howell
	JCO Oct 1 1994: 2113–2120. [Abstract] [PDF]
	Renal tolerance of cisplatin in patients more than 80 years old
	A Thyss, L Saudes, J Otto, A Creisson, MH Gaspard, O Dassonville, and M Schneider
	JCO Oct 1 1994: 2121–2125. [Abstract] [PDF]
	Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group
	DM Green, JB Beckwith, NE Breslow, P Faria, J Moksness, JZ Finklestein, P Grundy, PR Thomas, T Kim, and S Shochat
	JCO Oct 1 1994: 2126–2131. [Abstract] [PDF]
	Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group
	DM Green, NE Breslow, JB Beckwith, J Moksness, JZ Finklestein, and GJ D'Angio
	JCO Oct 1 1994: 2132–2137. [Abstract] [PDF]
	Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation
	PJ Shaw, ME Bergin, MA Burgess, L Dalla Pozza, SJ Kellie, G Rowell, MM Stevens, BH Webster, and KF Bradstock
	JCO Oct 1 1994: 2138–2145. [Abstract] [PDF]
	Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia
	W Reinisch, M Willheim, M Hilgarth, C Gasche, R Mader, S Szepfalusi, G Steger, R Berger, K Lechner, and G Boltz-Nitulescu
	JCO Oct 1 1994: 2146–2152. [Abstract] [PDF]
	Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high- grade lymphoma responsive to ProMACE-based combination chemotherapy [published erratum appears in J Clin Oncol 1996 Jun;14(6):1969]
	DL Longo, PL Duffey, ES Jaffe, M Raffeld, SM Hubbard, RI Fisher, RE Wittes, VT DeVita, Jr, and RC Young
	JCO Oct 1 1994: 2153–2159. [Abstract] [PDF]
	ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience
	SP Hunger, MP Link, and SS Donaldson
	JCO Oct 1 1994: 2160–2166. [Abstract] [PDF]
	Effect of treatment on the prognostic value of S-phase fraction in non- Hodgkin's lymphoma
	H Joensuu, R Ristamaki, KO Soderstrom, and S Jalkanen
	JCO Oct 1 1994: 2167–2175. [Abstract] [PDF]
	High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor- mobilized peripheral-blood stem cells
	A Nademanee, I Sniecinski, GM Schmidt, AC Dagis, MR O'Donnell, DS Snyder, PM Parker, AS Stein, EP Smith, and A Molina
	JCO Oct 1 1994: 2176–2186. [Abstract] [PDF]
	Secondary malignancies after bone marrow transplantation in adults
	R Lowsky, J Lipton, G Fyles, M Minden, J Meharchand, I Tejpar, H Atkins, S Sutcliffe, and H Messner
	JCO Oct 1 1994: 2187–2192. [Abstract] [PDF]
	Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia
	EK Rowinsky, A Adjei, RC Donehower, SD Gore, RJ Jones, PJ Burke, YC Cheng, LB Grochow, and SH Kaufmann
	JCO Oct 1 1994: 2193–2203. [Abstract] [PDF]
	Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin
	RM Navari, HG Kaplan, RJ Gralla, SM Grunberg, R Palmer, and D Fitts
	JCO Oct 1 1994: 2204–2210. [Abstract] [PDF]
	Are informed consent forms that describe clinical oncology research protocols readable by most patients and their families?
	SA Grossman, S Piantadosi, and C Covahey
	JCO Oct 1 1994: 2211–2215. [Abstract] [PDF]
	Neurotoxicity of purine analogs: a review
	BD Cheson, DA Vena, FM Foss, and JM Sorensen
	JCO Oct 1 1994: 2216–2228. [Abstract] [PDF]
Karnofsky Memorial Lecture. Natural history of small breast cancers
S Hellman
JCO Oct 1 1994: 2229–2234. [PDF]
Etoposide for metastatic breast cancer
B Meisenberg
JCO Oct 1 1994: 2235a. [PDF]
Are 5-hydroxytryptamine-3 receptor antagonists efficient antiemetics for chemotherapy-induced delayed emesis and do they remain effective over subsequent cycles?
A Adenis and J Bonneterre
JCO Oct 1 1994: 2235b–2236. [PDF]
Intensive chemotherapy with autologous peripheral-blood stem-cell rescue in metastatic breast cancer
RO Dillman and NM Barth
JCO Oct 1 1994: 2237a. [PDF]
Paclitaxel-induced "recall" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb
J Shapiro and GE Richardson
JCO Oct 1 1994: 2237b–2238. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.